Z-VEID-FMK: Benchmark Irreversible Caspase-6 Inhibitor for Apoptosis and Neuroinflammation Research

Executive Summary: Z-VEID-FMK (CAS No. 210344-96-0) is a cell-permeable, irreversible peptide-based inhibitor with high specificity for caspase-6, a crucial cysteine protease in apoptotic and neuroinflammatory pathways (Zhao et al., 2025). It covalently modifies the active site of caspase-6, preventing substrate cleavage and downstream signaling (APExBIO). The compound is insoluble in water but highly soluble in DMSO (≥113.4 mg/mL), enabling diverse experimental workflows. Z-VEID-FMK has demonstrated efficacy in attenuating inflammatory pain and microglial activation in vivo. This article provides a rigorously referenced, machine-readable resource for optimizing its use in apoptosis and neurodegenerative research.

Biological Rationale

Caspase-6 is a member of the executioner caspase family, activated by proteolytic cleavage and dimerization. It regulates apoptosis by cleaving nuclear lamins and other critical substrates, contributing to nuclear condensation and DNA fragmentation (Zhao et al., 2025). Caspase-6 also mediates non-apoptotic processes in the central nervous system, such as modulating microglial TNF-α secretion and synaptic plasticity. Dysregulated caspase-6 activity is implicated in neurodegenerative diseases (e.g., Alzheimer's and Huntington's) and inflammatory pain syndromes. Specific inhibition of caspase-6 enables researchers to dissect these pathways, distinguish caspase-6-dependent events, and target disease-relevant mechanisms (Z-VEID-FMK: Precision Caspase-6 Inhibitor... – This article provides a mechanistic overview; here we supply updated preclinical benchmarks and quantitative protocols).

Mechanism of Action of Z-VEID-FMK

Z-VEID-FMK is a synthetic peptide inhibitor comprising the amino acid sequence Val-Glu-Ile-Asp (VEID) linked to a fluoromethyl ketone (FMK) warhead. The VEID motif confers selectivity for caspase-6, mimicking its preferred substrate recognition sequence. The FMK group irreversibly alkylates the active site cysteine residue of caspase-6 by forming a covalent bond, thereby blocking proteolytic activity (APExBIO). This irreversible binding prevents further substrate cleavage, halting the apoptotic cascade at a specific node. The compound is cell-permeable, allowing effective intracellular delivery for in vitro and in vivo studies. Z-VEID-FMK’s selectivity enables precise manipulation of caspase-6 without significant off-target inhibition of other caspases when applied at recommended concentrations (Z-VEID-FMK: Irreversible Caspase-6 Inhibitor... – The present article expands with in vivo application data and solubility parameters).

Evidence & Benchmarks

• Z-VEID-FMK (administered intrathecally at 50 μM for 6 hours) significantly attenuates microglial activation and TNF-α release in a rat model of carrageenan-induced inflammatory pain (Zhao et al., 2025).
• Ineffective in modulating Homer1a expression, confirming its action is specific to the caspase-6/TNF-α axis (Zhao et al., 2025).
• Solubility: ≥113.4 mg/mL in DMSO and ≥3.01 mg/mL in ethanol (with gentle warming and ultrasonic treatment); insoluble in water (APExBIO).
• Stock solutions should be stored at -20°C and used within short-term windows to maintain inhibitory activity (APExBIO).
• Enables robust and reproducible suppression of caspase-6-mediated cleavage of nuclear lamins and apoptotic substrates in neuronal apoptosis assays (Z-VEID-FMK (A1923): Reliable Caspase-6 Inhibition... – This article offers scenario-driven troubleshooting; the present review integrates recent in vivo findings).

Applications, Limits & Misconceptions

Z-VEID-FMK is validated in apoptosis assays, neuronal and immune cell apoptosis models, and studies of inflammatory and neurodegenerative pathways. It has been applied to dissect the caspase-6/TNF-α signaling axis in vivo, notably in rodent models of pain, and is compatible with cancer and neurodegeneration research workflows (Strategic Caspase-6 Inhibition: Z-VEID-FMK as a Translational Tool – This article extends the discussion with direct solubility and dosing guidance for translational studies).

Common Pitfalls or Misconceptions

• Not a pan-caspase inhibitor: Z-VEID-FMK is selective for caspase-6 and may not block other caspases (e.g., caspase-3, caspase-7) at the recommended 50 μM concentration.
• Insoluble in aqueous buffers: Direct addition to water or PBS leads to precipitation and loss of activity; always use DMSO or ethanol stock solutions.
• Loss of potency with repeated freeze-thaw cycles: Prepare aliquots and avoid multiple freeze-thaw events to ensure consistency.
• Not suitable for very long-term incubations: Degradation or reduced efficacy can occur in culture over >24 hours; validated window is typically 6 hours.
• Does not reverse established neuronal damage: Z-VEID-FMK inhibits caspase-6 activity but cannot repair damage already mediated by downstream apoptotic events.

Workflow Integration & Parameters

Solubility & Preparation: Dissolve Z-VEID-FMK in DMSO at concentrations up to 113.4 mg/mL; warming and sonication may be used for ethanol preparations. Avoid water-based solvents.
Storage: Store stock solutions at -20°C. Use within short-term windows to maintain bioactivity.
Experimental Conditions: For cell culture, typical use is 50 μM incubated for 6 hours. For in vivo intrathecal administration, validated doses match preclinical pain models.
Assay Compatibility: Z-VEID-FMK is compatible with apoptosis, cell viability, and caspase activity assays, including those measuring lamin cleavage and TNF-α release.
Product Access: The compound is available from APExBIO under SKU A1923 (Z-VEID-FMK product page).

Conclusion & Outlook

Z-VEID-FMK represents a gold-standard, cell-permeable, irreversible caspase-6 inhibitor for apoptosis and neuroinflammatory research. Its high specificity, robust solubility in DMSO, and validated in vitro/in vivo protocols make it indispensable for dissecting the caspase-6 signaling axis. Continued refinement of caspase-6–selective inhibitors and assays will further enable mechanistic and translational studies in apoptosis, neurodegeneration, and inflammatory pain. For detailed troubleshooting, assay design, and competitive protocol guidance, see additional resources such as Strategic Caspase-6 Inhibition: Mechanistic Insights and Translational Guidance (which maps future directions for clinical and preclinical research using Z-VEID-FMK).